FACTS ABOUT MBL77 REVEALED

Besides ibrutinib, patients with M-CLL, devoid of TP53 aberrations and fit sufficient to tolerate FCR therapy, should still be good candidates for that latter, with the gain becoming this therapy can be finished in six months when ibrutinib needs to be taken indefinitely. This selection will be significantly important for non-compliant individuals